Adcoris

Adcoris is a clinical-stage innovative biotechnology company dedicated to developing next-generation bioconjugation technologies, focusing on the research and development of differentiated innovative biologics in the fields of immuno-oncology, infectious diseases, autoimmune diseases, and metabolic disorders. The company has established two new drug R&D platforms, Adcoris-ADC and Adcoris-AXC, to accelerate the design and synthesis of Payloads and Linkers. By improving conjugation methods and leveraging strong preclinical research capabilities, the company aims to address key industry challenges.